Literature DB >> 12133724

A view to a kill: ligands for Bcl-2 family proteins.

Stacey E Rutledge1, Jason W Chin, Alanna Schepartz.   

Abstract

Apoptosis is the essential process of programmed cell death that, in multicellular organisms, regulates development and maintains homeostasis. Defects in the apoptotic molecular machinery that result in either excessive or insufficient apoptosis are observed in a remarkably wide range of human disease, prompting intense interest in pro- and anti-apoptotic proteins as therapeutic targets. A number of recent reports have described the discovery of ligands for anti-apoptotic Bcl-2 family proteins by a variety of approaches, including computational, combinatorial and evolutionary strategies. Both the design of ligands and the exploration of their mechanisms of action have been greatly enhanced by recent high-resolution structure determinations of proteins from this family. Several of the newly discovered ligands promote apoptosis, and some do so even in the face of overexpressed anti-apoptotic Bcl-2 proteins. Ligands that overcome the protective effects associated with up-regulation of anti-apoptotic Bcl-2 proteins represent especially promising therapeutic leads.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133724     DOI: 10.1016/s1367-5931(02)00352-6

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  17 in total

1.  Molecular recognition of protein surfaces: high affinity ligands for the CBP KIX domain.

Authors:  Stacey E Rutledge; Heather M Volkman; Alanna Schepartz
Journal:  J Am Chem Soc       Date:  2003-11-26       Impact factor: 15.419

2.  Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL.

Authors:  Deyun Wang; Wei Liao; Paramjit S Arora
Journal:  Angew Chem Int Ed Engl       Date:  2005-10-14       Impact factor: 15.336

3.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

Authors:  Mark F van Delft; Andrew H Wei; Kylie D Mason; Cassandra J Vandenberg; Lin Chen; Peter E Czabotar; Simon N Willis; Clare L Scott; Catherine L Day; Suzanne Cory; Jerry M Adams; Andrew W Roberts; David C S Huang
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

4.  Helix stability of oligoglycine, oligoalanine, and oligo-β-alanine dodecamers reflected by hydrogen-bond persistence.

Authors:  Chengyu Liu; Jay W Ponder; Garland R Marshall
Journal:  Proteins       Date:  2014-09-20

5.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

Review 6.  BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions.

Authors:  Victoria Del Gaizo Moore; Anthony Letai
Journal:  Cancer Lett       Date:  2012-01-08       Impact factor: 8.679

7.  Bim is a suppressor of Myc-induced mouse B cell leukemia.

Authors:  Alexander Egle; Alan W Harris; Philippe Bouillet; Suzanne Cory
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

8.  Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines.

Authors:  Luigi Aloj; Antonella Zannetti; Corradina Caracó; Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

9.  Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma.

Authors:  Silvana Del Vecchio; Antonella Zannetti; Luigi Aloj; Corradina Caracò; Andrea Ciarmiello; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-30       Impact factor: 9.236

10.  Miniature protein ligands for EVH1 domains: interplay between affinity, specificity, and cell motility.

Authors:  Jennifer H Holtzman; Kamil Woronowicz; Dasantila Golemi-Kotra; Alanna Schepartz
Journal:  Biochemistry       Date:  2007-11-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.